GREENVILLE, S.C., Nov. 12 /PRNewswire-FirstCall/ -- Signalife, Inc. a medical device company invites participants to its demonstration of the Fidelity 100 Heart Monitor at the American Heart Association, 2006, Scientific Sessions being held at McCormick Place in Chicago, IL, November 12 - 15, 2006.
At the AHA sessions, visitors will be able to see a world class sprinter garnering a full, 12-lead, ECG signal from Signalife's flagship Fidelity 100 device. Signalife views this as the ultimate test of its device in a most grueling ambulatory environment. Willie Gault, Super Bowl winner and Olympic Gold Medalist will be exhibiting the device live to demonstrate the Fidelity 100 signal quality and the importance of ambulatory testing. Mr. Gault will be available to discuss the collaboration between Signalife and the Athletes for Life Foundation, which is focused on expanding the reach of health care, on earlier detection of cardiovascular disease, and on better outcomes for all cardiovascular patients.
Signalife's technology is building a new era in cardiac monitoring. Our technology amplifies the cardiac signal and reads, records and displays clear data without the usual artifact -- providing clear useable data and greater diagnostic yield.
Visitors to the exhibit will also see Frost & Sullivan present Signalife with the 2006 Technology Innovation Award at a ceremony scheduled for November 13 at 2 PM for all Scientific Sessions' participants to attend.
There will be demonstrations in the Signalife exhibit, and all participants are invited to attend.
About Signalife
Signalife, Inc., is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.signalife.com/. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
